AUA2026 Spotlight: PARP-Inhibitor Combination Treatments for the Urologic Care Team
Thursday, May 14, 2026 5:30 PM to 6:30 PM · 1 hr. (America/New_York)
Ballroom B
Forum
Oncology: Prostate
Information
Your name badge for AUA2026 is required to gain entry into this activity. All attendees must pick-up their AUA2026 badge at Main Registration prior to arrival at the course location. AUA2025 Registration opens on Thursday, May 14 at 6:30 a.m.
Seating is first come, first serve.
AUA2026 Spotlight: PARP-Inhibitor Combination Treatments for the Urologic Care Team will address PARP-Inhibitors in the rapidly changing metastatic prostate cancer (mPC) landscape.
The PARP session is taking place on Thursday evening, May 14, 2026, immediately following the full day program, The Evolving Landscape of Advanced Prostate Cancer Treatment: A Guidelines and Case-Based Discussion. Presented by the AUA in partnership with the Society for Urologic Oncology (SUO), this will mark the 10th year that The Evolving Landscape of Advanced Prostate Cancer Treatment has been offered in conjunction with the AUA Annual Meeting. The program continues to grow in popularity every year.
After participating in this CME activity, participants will be able to:
1. Integrate biomarker and genetic testing principles into clinical workflows for patients with metastatic prostate cancer, including when to order testing, how to interpret HRR mutation results (inclusive of BRCA and non-BRCA), and how to address barriers to testing through multidisciplinary coordination.
2. Explain the mechanism of action of PARP inhibitors and the biological and clinical rationale for their use—both as monotherapy and in combination approaches—in the treatment of mPC.
3. Evaluate emerging efficacy and safety data on PARPi combinations, including patient subgroup analyses, sequencing strategies, and the role of combination therapy in different stages of mPC.
4. Apply best practices for side effect monitoring and mitigation in patients receiving PARP inhibitors alone or in combination, leveraging the multidisciplinary team for optimal therapy management and patient quality of life.
5. Implement guideline-concordant care strategies in practice, including genetic testing workflow implementation, coordination among care team members, and patient engagement in shared decision-making and clinical trial enrollment.
6. Utilize current evidence-based guidelines to select and sequence PARP inhibitor therapy for patients with mPC, optimizing oncologic outcomes while individualizing care based on molecular profile and patient-specific factors.
Acknowledgements:
Support provided by independent educational grants from AstraZeneca, Merck & Co., Inc and Pfizer, Inc.
Seating is first come, first serve.
AUA2026 Spotlight: PARP-Inhibitor Combination Treatments for the Urologic Care Team will address PARP-Inhibitors in the rapidly changing metastatic prostate cancer (mPC) landscape.
The PARP session is taking place on Thursday evening, May 14, 2026, immediately following the full day program, The Evolving Landscape of Advanced Prostate Cancer Treatment: A Guidelines and Case-Based Discussion. Presented by the AUA in partnership with the Society for Urologic Oncology (SUO), this will mark the 10th year that The Evolving Landscape of Advanced Prostate Cancer Treatment has been offered in conjunction with the AUA Annual Meeting. The program continues to grow in popularity every year.
After participating in this CME activity, participants will be able to:
1. Integrate biomarker and genetic testing principles into clinical workflows for patients with metastatic prostate cancer, including when to order testing, how to interpret HRR mutation results (inclusive of BRCA and non-BRCA), and how to address barriers to testing through multidisciplinary coordination.
2. Explain the mechanism of action of PARP inhibitors and the biological and clinical rationale for their use—both as monotherapy and in combination approaches—in the treatment of mPC.
3. Evaluate emerging efficacy and safety data on PARPi combinations, including patient subgroup analyses, sequencing strategies, and the role of combination therapy in different stages of mPC.
4. Apply best practices for side effect monitoring and mitigation in patients receiving PARP inhibitors alone or in combination, leveraging the multidisciplinary team for optimal therapy management and patient quality of life.
5. Implement guideline-concordant care strategies in practice, including genetic testing workflow implementation, coordination among care team members, and patient engagement in shared decision-making and clinical trial enrollment.
6. Utilize current evidence-based guidelines to select and sequence PARP inhibitor therapy for patients with mPC, optimizing oncologic outcomes while individualizing care based on molecular profile and patient-specific factors.
Acknowledgements:
Support provided by independent educational grants from AstraZeneca, Merck & Co., Inc and Pfizer, Inc.
Of Interest To
Advanced Practice Providers (APP)FellowsResidentsYoung Urologists
